Abstract:Active tuberculosis (aTB) remains a major killer from infectious disease, partially due to delayed diagnosis and hence treatment. Classical microbiological methods are slow and lack sensitivity, molecular techniques are costly and often unavailable. Moreover, available immuno-diagnostic tests lack sensitivity and do not differentiate between aTB and latent TB infection (LTBI). Here, we evaluated the performance of the combined measurement of different chemokines/cytokines induced by two different stage-specific mycobacterial antigens, Early-secreted-antigenic target-6 (ESAT-6) and Heparin-binding-haemagglutinin (HBHA), after a short in vitro incubation of either peripheral blood mononuclear cells (PBMC) or whole blood (WB). Blood samples were collected from a training cohort comprising 22 aTB patients, 22 LTBI subjects and 17 non-infected controls. The concentrations of 13 cytokines were measured in the supernatants. Random forest analysis identified the best markers to differentiate M. tuberculosis-infected from non-infected subjects, and the most appropriate markers to differentiate aTB from LTBI. Logistic regression defined predictive abilities of selected combinations of cytokines, first on the training and then on a validation cohort (17 aTB, 27 LTBI, 25 controls). Combining HBHA- and ESAT-6-induced IFN-γ concentrations produced by PBMC was optimal to differentiate infected from non-infected individuals in the training cohort (100% correct classification), but 2/16 (13%) patients with aTB were misclassified in the validation cohort. ESAT-6-induced-IP-10 combined with HBHA-induced-IFN-γ concentrations was selected to differentiate aTB from LTBI, and correctly classified 82%/77% of infected subjects as aTB or LTBI in the training/validation cohorts, respectively. Results obtained on WB also selected ESAT-6- and HBHA-induced IFN-γ concentrations to provided discrimination between infected and non-infected subjects (89%/90% correct classification in the training/validation cohorts). Further identification of aTB patients among infected subjects was best achieved by combining ESAT-6-induced IP-10 with HBHA-induced IL-2 and GM-CSF. Among infected subjects, 90%/93% of the aTB patients were correctly identified in the training/validation cohorts. We therefore propose a two steps strategy performed on 1 mL WB for a rapid identification of patients with aTB. After elimination of most non-infected subjects by combining ESAT-6 and HBHA-induced IFN-γ, the combination of IP-10, IL-2 and GM-CSF released by either ESAT-6 or HBHA correctly identifies most patients with aTB.

C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay

Rapid decrease in IL-1Ra and IP-10 plasma levels following tuberculosis treatment initiation

Serum pro-inflammatory biomarkers associated with improvement in quality of life in pulmonary tuberculosis

Immuno-Diagnosis of Active Tuberculosis by a Combination of Cytokines/Chemokines Induced by Two Stage-Specific Mycobacterial Antigens: A Pilot Study in a Low TB Incidence Country

Plasma cytokine levels characterize disease pathogenesis and treatment response in tuberculosis patients

Analysis Of Plasma Cytokine And Chemokine Profiles In Patients With And Without Tuberculosis By Liquid Array-Based Multiplexed Immunoassays

Tuberculosis Severity Predictive Model Using Mtb Variants and Serum Biomarkers in a Colombian Cohort of APTB Patients

A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings

Evaluation of the Diagnostic Potential of IP-10 and IL-2 As Biomarkers for the Diagnosis of Active and Latent Tuberculosis in a BCG-Vaccinated Population

IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy

IP-10 and MIG Are Compartmentalized at the Site of Disease During Pleural and Meningeal Tuberculosis and Are Decreased after Antituberculosis Treatment

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis

The Association Between Mycobacteria-Specific Antigen-Induced Cytokines and Host Response to Latent Tuberculosis Infection Treatment in a Chinese Population

Serum Levels of Inhibitory Costimulatory Molecules and Correlations with Levels of Innate Immune Cytokines in Patients with Pulmonary Tuberculosis

Distinct TB-antigen stimulated cytokine profiles as predictive biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis

The Serum Th1 and Th2 Cytokines Levels in Active Tuberculosis Patients Before and after 2 Month Anti-Tb Treatment

Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis

Plasma Immune Biomarkers Predictive of Progression to Active Tuberculosis in Household Contacts of TB Patients

Exploring cytokine dynamics in tuberculosis: A comparative analysis of patients and controls with insights from three-week antituberculosis intervention

Biomarkers Correlated with Tuberculosis Preventive Treatment Response: A Systematic Review and Meta-Analysis

Antigen-specific chemokine profiles as biomarkers for detecting Mycobacterium tuberculosis infection